OLBA HEALTHCARE (2689) Q4 2026 earnings summary

Executive summary

• FY2026 net sales reached a record ¥126,595 million, up 3.2% year over year; operating profit fell 15.2% to ¥1,679 million and profit attributable to owners of parent fell 22.2% to ¥1,112 million.

• Revenue grew for a sixth consecutive year, while operating income declined for a second consecutive year amid margin pressure, higher SG&A and one-time system security and integration costs.

• Comprehensive income decreased 7.4% year over year to ¥1,294 million.

Financial highlights

• Gross profit rose to ¥14,179 million; SG&A increased 4.8% to ¥12,498 million, while operating margin declined to 1.3% from 1.6%.

• Recurring profit fell 15.2% to ¥1.664 billion; basic EPS dropped to ¥187.67 from ¥241.43.

• Medical equipment consumables sales rose 3.5% to ¥107 billion, while equipment sales fell 3.0% to ¥14.2 billion.

Outlook and guidance

• FY2028 targets are net sales of ¥142 billion and operating income of ¥2.7 billion, supported by productivity initiatives, ICT use, logistics innovation and new businesses.

• VISION 2030 aims to reach top domestic medical-device trading-company status, generate 20% of operating income overseas and launch more than 30 new products and services.

• No consolidated FY2027 financial forecasts have been provided; the FY2027 dividend remains undecided pending the September 1, 2026 DVx Inc. integration.